|
SF3A3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.39509531599447E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.24989998748515E-09 |
| Normal-vs-Stage2 |
3.05749999995886E-06 |
| Normal-vs-Stage3 |
1.31239996647992E-09 |
| Normal-vs-Stage4 |
1.36840538900174E-11 |
| Stage1-vs-Stage2 |
9.703800E-01 |
| Stage1-vs-Stage3 |
4.098000E-01 |
| Stage1-vs-Stage4 |
1.290260E-02 |
| Stage2-vs-Stage3 |
5.935000E-01 |
| Stage2-vs-Stage4 |
9.307800E-02 |
| Stage3-vs-Stage4 |
1.311410E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.9694029153643E-11 |
| Normal-vs-AfricanAmerican |
2.262700E-03 |
| Normal-vs-Asian |
4.03609999999333E-06 |
| Caucasian-vs-AfricanAmerican |
2.628600E-01 |
| Caucasian-vs-Asian |
4.582400E-01 |
| AfricanAmerican-vs-Asian |
6.075800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.24670052059628E-10 |
| Normal-vs-Female |
4.1248005011596E-10 |
| Male-vs-Female |
2.557400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.9835999953699E-08 |
| Normal-vs-Age(41-60Yrs) |
3.81520004477665E-09 |
| Normal-vs-Age(61-80Yrs) |
5.42420552918088E-11 |
| Normal-vs-Age(81-100Yrs) |
6.658700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.422000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.400440E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.666200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.549200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.791600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.802400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.223600E-03 |
| Classical-VS-Follicular |
3.611800E-04 |
| Classical-VS-Other |
1.060210E-01 |
| Classical-VS-Normal |
3.22650000050828E-08 |
| Tall-VS-Follicular |
9.310000E-01 |
| Tall-VS-Other |
8.914600E-01 |
| Tall-VS-Normal |
6.34870001015031E-09 |
| Follicular-VS-Other |
8.397200E-01 |
| Follicular-VS-Normal |
1.26110011322567E-10 |
| Other-VS-Normal |
1.015510E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.18730003606515E-09 |
| Normal-vs-N1 |
6.06847905260111E-13 |
| N0-vs-N1 |
1.390090E-02 |
|
|
